• search
Small Molecules Manufacturing Services Small Molecules Manufacturing Services

Small Molecules Manufacturing Services

We are committed to provide high-quality and phase appropriate manufacturing services for small molecules.

We provide clinical supplies and commercial supplies of APIs through our 8 US FDA-inspected cGMP manufacturing sites across India, UK and Mexico. We operate thousands of kilo liters of reactor volumes with thousand-plus reactors in intermediate blocks and clean rooms out of which hundreds of reactors can cater to special technologies like High Potent APIs (HPAPIs), Peptides, Steroids and Prostaglandins. All our plants are operated by cGMP (ICH Q7a) and regularly inspected/audited by international authorities and customers.  

We offer manufacturing services in a wide range of scales and are expanding our capabilities while maintaining high safety standards. With Electronic Batch Production Record (EBPR) and Electronic Lab Notebook (ELN), we are expanding our digitalization functionality.  

Our facilities are operated with sustainability as one of the focus areas with principles around environmental and social governance intact. Operations of our sites are linked with processes around: Green Chemistry, waste minimization, waste management, water neutrality, emission control, reducing carbon footprint and usage of renewable power, people practice, community development activities, and a strong focus on ethics compliance and transparency.

Speak to our experts

Why Aurigene Small Molecules Manufacturing Services?

20+ years of legacy, worked on 500+ molecules, 15+ commercialized

Plants across continents (India, UK, Mexico)

Global regulatory inspections (USFDA, PMDA, EDQM, MHRA etc.)

Wide range of technologies & niche reactions (Peptide, Steroid, High potent)

High quality and flexible scale production

Extensive process safety and hazard analysis

Integrated QC testing and release

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

rightCaptcha

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...

Read More
cGMP flyer

cGMP Development and Manufacturing Services

Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...

Read More
Solid dispersion development to enhance solubility and oral bioavailability for rodent toxicology studies

Solid dispersion development to enhance solubility and oral bioavailability for rodent toxicology studies

Background: Develop oral liquid dosage form of an IND candidate (small molecule) suitable for chronic toxicology studies in rats. Must meet required systemic exposure and shall be dose proportional. Developed vehicle or used excipients shall be safe for chronic preclinical toxicology studies. Challenges: Low oral bioavailability Practically insoluble in bio relev...

Read More

An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives

2016

A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack